Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company that specializes in the development and commercialization of innovative therapies for patient populations in endocrinology and neurology. Rather than discovering new molecules, Xeris leverages its proprietary formulation technology platforms, XeriSol and XeriJect, to create ready-to-use, liquid-stable injectable and infusible medications from existing drugs. This approach eliminates the need for complex reconstitution or intravenous infusions, improving patient convenience and adherence.
The company's commercial portfolio consists of three primary FDA-approved products: Recorlev (levoketoconazole) for the treatment of endogenous Cushing's syndrome, Gvoke (glucagon) for severe hypoglycemia in patients with diabetes, and Keveyis (diclofenamide) for primary periodic paralysis. In the first quarter of 2026, Xeris generated $83.1 million in total revenue, driven predominantly by Recorlev ($49.8 million), followed by Gvoke ($20.8 million) and Keveyis ($11.9 million). The company also generates revenue through strategic partnerships, applying its XeriJect technology to the large-molecule biologics of other pharmaceutical firms in exchange for milestone payments and royalties. Geographically, Xeris operates primarily in the United States. Its pipeline includes XP-8121, a once-weekly subcutaneous levothyroxine injection for hypothyroidism, further expanding its focus on high-need therapeutic areas.
